Source comparison
MOTS-c Downstream Effects: Peptide Comparison
MOTS-c AMPK activation → PGC-1α upregulation Insulin sensitivity, mitochondrial biogenesis, fatty acid oxidation 6–12 hours 72–96 hours per dose Metabolic syndrome, insulin resistance, aging-related metabolic decline SS-31 (Elamipretide) Cardiolipin stabilizat
This comparison does not assign a generated winner or score.
- MOTS-c
- AMPK activation → PGC-1α upregulation
- Insulin sensitivity, mitochondrial biogenesis, fatty acid oxidation
- 6–12 hours
- 72–96 hours per dose
- Metabolic syndrome, insulin resistance, aging-related metabolic decline
- SS-31 (Elamipretide)
- Cardiolipin stabilization in inner mitochondrial membrane
- Reduces electron leak, improves ATP synthesis efficiency
- 2–4 hours
- 24–36 hours
- Mitochondrial myopathies, heart failure, neurodegenerative disease
- Humanin
- STAT3 signaling, BAX inhibition
- Apoptosis resistance, neuroprotection, insulin signaling modulation
- 4–8 hours
- 48–72 hours
- Alzheimer's disease models, ischemic injury, age-related cognitive decline
- NAD+ precursors (NMN/NR)
- NAD+ repletion → sirtuin activation
- Mitochondrial function, DNA repair, circadian rhythm regulation
- 1–2 hours
- 12–24 hours (daily dosing required)
- Aging research, metabolic health, neuroprotection